Man Without Human Heart Hikes More Than 400 Miles
1st SynCardia Total Artificial Heart Patient in the Pacific Northwest
Discharged from the Hospital Waits for Matching Donor Heart
TUCSON, Ariz. – Aug. 1, 2012 – Hiking up to six miles every day isn't for the faint of heart. Luckily for Chris Marshall, he doesn't have one. Marshall, the first SynCardia temporary Total Artificial Heart patient in the Pacific Northwest to leave the hospital using the Freedom® portable driver, has logged more than 400 miles of hiking since being discharged from University of Washington Medical Center on March 29.
"I've walked just about 437 miles since I was discharged," said Marshall. "I feel so much better with the Total Artificial Heart than I was feeling before. My color is greatly improved, my vitality is going up. With the Total Artificial Heart and the Freedom driver, I really get to go out and live life."
In 1999, Marshall was diagnosed with cardiomyopathy, a disease that destroys the heart muscle over time, and ventricular tachycardia, an irregular, fast heartbeat. Although his implanted defibrillator shocked his heart 30 times over a 12-year span, Marshall never let his heart condition slow him down.
“I actually did very well with a low heart ejection fraction for many years,” said Marshall. “My doctors did a really good job of managing me medically. I was doing a lot of hiking - 3 to 5 miles a day - with an ejection fraction around 20 percent. A healthy ejection fraction is around 50 to 70 percent. It was only this past fall that I started getting shortness of breath on level ground, which had never happened before.”
On Jan. 23, Marshall and his wife Kathy traveled from their home in Wasilla, Alaska, to Seattle for what was supposed to be a one-day heart evaluation. However, doctors discovered his heart was
functioning at less than 10 percent, and didn't think he would survive the flight home.
"I was walking 20 laps a day in the hospital hallways at a very fast clip," said Marshall. "So when my surgeon told me that he wanted to replace my heart with the Total Artificial Heart, it seemed kind of
Marshall’s surgeon, Dr. Nahush Mokadam, wanted to do the surgery on Feb. 6. As the date approached, it was up to Marshall to decide whether to proceed with implanting the SynCardia Total Artificial Heart.
“On Feb. 5, I ended up having ventricular tachycardia after walking my sixth lap around the hospital floor,” said Marshall. “I lost consciousness and when I woke up, I was lying on the floor with the IV pole next to me. After that, everyone agreed that the Total Artificial Heart wasn’t a bad idea.
“I told them yes, let’s go ahead with it.”
Marshall was implanted with the Total Artificial Heart during a six-hour procedure on Feb. 6. Seven weeks later, on March 21, he was discharged from University of Washington Medical Center using the Freedom portable driver to power his Total Artificial Heart. Since his discharge, Marshall has enjoyed hiking in the Seattle area with his wife Kathy and his golden retriever Gracie.
Weighing 13.5 pounds, the Freedom portable driver is the world’s first wearable power supply for the SynCardia Total Artificial Heart. The Freedom driver is CE approved for use in Europe and undergoing an FDA-approved Investigational Device Exemption (IDE) clinical study in the U.S.
UW Medicine slideshow narrated by Dr. Nahush A. Mokadam
About the SynCardia temporary Total Artificial Heart
SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, the SynCardia Total Artificial Heart is currently approved as a bridge to transplant for people suffering from end stage heart failure affecting both sides of the heart (biventricular failure). There have been more than 1,250 implants of the Total Artificial Heart, accounting for more than 335 patient years of life on the device.
Similar to a heart transplant, the SynCardia Total Artificial Heart replaces both failing heart ventricles and the four heart valves. It is the only device that eliminates the symptoms and source of end stage biventricular failure. Unlike a donor heart, the Total Artificial Heart is immediately available at 93 SynCardia Certified Centers worldwide with 35 others in the process of certification.
The Total Artificial Heart provides immediate, safe blood flow of up to 9.5 liters per minute through each ventricle. This high volume of blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.
Forbes Ranks SynCardia #69 Among "America's Most Promising Companies"
In its February 2013 issue, Forbes selected SynCardia as one of "America's Most Promising Companies" for the second consecutive year. On the list of 100 privately held, high-growth companies with bright futures, SynCardia was selected #69, moving up eight spots from its #77 ranking last year. See the full list of SynCardia Awards & Recognition.